Overview

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

Status:
Recruiting

Trial end date:
2026-09-02

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.

Phase:

Phase 3

Details

Lead Sponsor:

UCB BIOSCIENCES, Inc.

Treatments:

Fenfluramine